Nemus Bioscience, Inc. is an early‐stage biopharmaceutical company developing proprietary prodrug cannabinoid therapeutics for ophthalmic, dermatological and metabolic diseases. The company leverages synthetic derivatives of naturally occurring cannabinoids, designed to improve bioavailability, tissue targeting and therapeutic efficacy. Nemus operates under an OTCMKTS listing and is headquartered in Houston, Texas.
The company’s pipeline includes multiple preclinical candidates, with lead programs focusing on ophthalmic and dermatological indications. Nemus’ ophthalmic portfolio targets conditions such as diabetic retinopathy and glaucoma through topical prodrug formulations intended to enhance drug penetration into ocular tissues. Its dermatological programs are aimed at inflammatory skin disorders, utilizing cannabinoid prodrugs to deliver anti‐inflammatory effects while minimizing systemic exposure.
In addition to eye and skin applications, Nemus is advancing metabolic disease programs, exploring cannabinoid prodrugs for non‐alcoholic fatty liver disease and obesity. The company employs in‐house chemistry and formulation expertise to optimize drug stability and performance. Nemus has established research collaborations with academic institutions to support preclinical pharmacology and toxicology studies, reinforcing its commitment to rigorous scientific validation.
Leadership at Nemus Bioscience includes Chief Executive Officer Daniel Gould, who brings experience in pharmaceutical development and corporate strategy. Under his guidance, the company has prioritized strengthening its intellectual property portfolio and advancing its lead candidates toward regulatory milestones. Nemus continues to expand its research capabilities in North America, positioning itself to address unmet medical needs with novel cannabinoid‐based therapies.
AI Generated. May Contain Errors.
